Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements regarding its product SLK and its comparison to BIMZELX, which led to significant stock price decline following disappointing clinical trial results [2][4][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to contact them for discussing legal options [1]. - The firm is investigating claims against MoonLake and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action [2]. - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the efficacy of SLK compared to BIMZELX [4]. Group 2: Financial Impact - On September 28, 2025, MoonLake announced that SLK failed to demonstrate competitive efficacy relative to BIMZELX, resulting in a stock price drop of $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [5]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities litigation [3]. Group 3: Company Background - MoonLake Immunotherapeutics is listed on NASDAQ under the ticker MLTX [2]. - The company is involved in the development of therapeutics, specifically focusing on Nanobodies and their clinical applications [4].

RT Neuralink (@neuralink)ALS is a neurodegenerative disease that gradually and relentlessly takes away bodily functions, such as the ability to speak.With Neuralink, we aim to restore the voices of those who have lost them. ...

Core Insights - Alnylam Pharmaceuticals has faced challenges in the last three months due to slowing sales at a key rival, raising concerns about the overall health of the transthyretin amyloidosis (TTR) market [1] Company Summary - Alnylam Pharmaceuticals is experiencing difficulties linked to competitive pressures in the TTR space, which may impact its market position and sales performance [1]

Core Viewpoint - The lawsuit against MoonLake Immunotherapeutics alleges that the company and its executives made false statements about the clinical efficacy of their drug candidate, sonelokimab, leading to a significant stock price drop of nearly 90% following disappointing trial results [2][3][4]. Summary by Sections Lawsuit Details - The lawsuit claims that MoonLake's assertions regarding the superiority of its Nanobody technology were misleading, particularly in comparison to the FDA-approved competitor BIMZELX [3]. - The stock price plummeted from $61.99 to $6.24, representing a 90% loss, after the VELA-2 trial failed to meet its primary endpoint and demonstrated inferior efficacy [4]. Timeline and Key Information - Class Period: March 10, 2024 – September 29, 2025 - Lead Plaintiff Deadline: December 15, 2025 - Significant Stock Drop: 90% loss on September 29, 2025, due to failed trial results [4]. Next Steps for Investors - Investors who purchased MoonLake stock during the specified class period and incurred substantial losses are encouraged to contact Hagens Berman to explore legal options and potential appointment as Lead Plaintiff [5]. About Hagens Berman - Hagens Berman is a global plaintiffs' rights firm that focuses on corporate accountability and has secured over $2.9 billion for clients in similar cases [7].

Core Points - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate sonelokimab (SLK) [8] - The lawsuit claims that MoonLake promoted SLK as superior to competing drugs while failing to disclose its lack of proven superiority [8] - Following the announcement of disappointing Phase 3 trial results, MoonLake's stock price dropped nearly 90%, resulting in significant investor losses [8] Allegation Details - The lawsuit covers all individuals and entities who purchased MoonLake common stock between March 10, 2024, and September 29, 2025 [8] - The complaint highlights that MoonLake's executives touted SLK's unique clinical advantages without revealing that it targeted the same molecules as UCB's BIMZELX [8] - The stock plummeted 89.9% on September 29, 2025, after the company disclosed that the VELA-2 trial did not achieve statistical significance due to unexpected events in the placebo group [8] Next Steps - Investors who suffered losses and wish to participate in the lawsuit must apply to the Court by December 15, 2025, to be appointed as lead plaintiff [8] - Interested parties can contact Bragar Eagel & Squire, P.C. for more information regarding their rights and the claims [4][5]

We recently published 10 Big Names Leaving Wall Street in the Dust; 4 at Fresh Highs. ImmunityBio Inc. (NASDAQ:IBRX) is one of the best performers on Friday. ImmunityBio jumped by 7.76 percent on Friday to close at $2.36 apiece after securing the green light of the European Medicines Agency (EMA) to sell its bladder cancer treatment Anktiva in Europe. In a statement, ImmunityBio Inc. (NASDAQ:IBRX) said that the EMA officially authorized Anktiva, in combination with Bacillus Calmette-Guerin (BCG), for th ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .Bret Jensen has over 13 years as a market analyst, helping investors find big winners in the biotech sector. Bret specializes in high beta sectors with potentially large investor returns.Bret leads the investing group The Biotech Forum, ...

Core Viewpoint - Allergy Therapeutics PLC is positioned well in the allergy immunotherapy market, demonstrating stable revenue and a strong market position despite shifts in product registration in Germany [3][5]. Financial Performance - The company reported an earnings per share (EPS) of -$0.007, which matched the estimated EPS [1][5]. - Revenue for the year ending June 2025 was reported at £55 million, stable compared to the previous year, with a 2% increase when adjusted for constant exchange rates [2]. Market Dynamics - There has been a rapid shift in Germany from non-registered to fully registered allergy immunotherapy products, altering the company's product mix more swiftly than anticipated [3]. - Demand for Allergy Therapeutics' registered treatments remains strong, indicating a solid market position [3][5]. Financial Position - The company has significantly strengthened its balance sheet by repaying a £55 million shareholder loan facility and securing a new £50 million uncommitted loan facility [4][5]. - This financial flexibility is crucial as the company prepares for a key decision in 2026 [4].

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

LA JOLLA, CA, Dec. 12, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the closing of its previously announced public offering of an aggregate of 10,666,667 shares of its common stock (or common stock equivalents in lieu thereof), Series F warrants to purchase up to 10,666,667 shares of com ...